A Mechanistic Pharmacokinetic Model for Intrathecal Administration of Antisense Oligonucleotides

Overview

Journal Front Physiol

Date 2023 Jun 19

PMID 37334053

Authors

Andreas A Linninger

Dipak Barua

Yaming Hang

Sergio Iadevaia

Majid Vakilynejad

Affiliations

Soon will be listed here.

Abstract

Intrathecal administration is an important mode for delivering biological agents targeting central nervous system (CNS) diseases. However, current clinical practices lack a sound theorical basis for a quantitative understanding of the variables and conditions that govern the delivery efficiency and specific tissue targeting especially in the brain. This work presents a distributed mechanistic pharmacokinetic model (DMPK) for predictive analysis of intrathecal drug delivery to CNS. The proposed DMPK model captures the spatiotemporal dispersion of antisense oligonucleotides (ASO) along the neuraxis over clinically relevant time scales of days and weeks as a function of infusion, physiological and molecular properties. We demonstrate its prediction capability using biodistribution data of antisense oligonucleotide (ASO) administration in non-human primates. The results are in close agreement with the observed ASO pharmacokinetics in all key compartments of the central nervous system. The model enables determination of optimal injection parameters such as intrathecal infusion volume and duration for maximum ASO delivery to the brain. Our quantitative model-guided analysis is suitable for identifying optimal parameter settings to target specific brain regions with therapeutic drugs such as ASOs.

Citing Articles

Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.

Ruchi R, Raman G, Kumar V, Bahal R Expert Opin Drug Discov. 2024; 20(1):63-80.

PMID: 39653607 PMC: 11823135. DOI: 10.1080/17460441.2024.2440095.

Effects of buoyancy on the dispersion of drugs released intrathecally in the spinal canal.

Alaminos-Quesada J, Gutierrez-Montes C, Coenen W, Sanchez A J Fluid Mech. 2024; 985.

PMID: 38774672 PMC: 11108058. DOI: 10.1017/jfm.2024.297.

Determination of spinal tracer dispersion after intrathecal injection in a deformable CNS model.

Ayansiji A, Gehrke D, Baralle B, Nozain A, Singh M, Linninger A Front Physiol. 2023; 14:1244016.

PMID: 37817986 PMC: 10561273. DOI: 10.3389/fphys.2023.1244016.

Nucleic acid-based therapeutics for the treatment of central nervous system disorders.

McCartan R, Khorkova O, Volmar C, Wahlestedt C Front Genet. 2023; 14:1250276.

PMID: 37662844 PMC: 10468602. DOI: 10.3389/fgene.2023.1250276.

References

Sullivan J, Mazur C, Wolf D, Horky L, Currier N, Fitzsimmons B . Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system. J Transl Med. 2020; 18(1):309. PMC: 7414676. DOI: 10.1186/s12967-020-02461-2. View

Khani M, Lawrence B, Sass L, Gibbs C, Pluid J, Oshinski J . Characterization of intrathecal cerebrospinal fluid geometry and dynamics in cynomolgus monkeys (macaca fascicularis) by magnetic resonance imaging. PLoS One. 2019; 14(2):e0212239. PMC: 6392269. DOI: 10.1371/journal.pone.0212239. View

Bernards C, Hill H . Physical and chemical properties of drug molecules governing their diffusion through the spinal meninges. Anesthesiology. 1992; 77(4):750-6. DOI: 10.1097/00000542-199210000-00020. View

Hsu Y, Hettiarachchi H, Zhu D, Linninger A . The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth Analg. 2012; 115(2):386-94. DOI: 10.1213/ANE.0b013e3182536211. View

Ummenhofer W, Arends R, Shen D, Bernards C . Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology. 2000; 92(3):739-53. DOI: 10.1097/00000542-200003000-00018. View

Tangen K, Nestorov I, Verma A, Sullivan J, Holt R, Linninger A . In Vivo Intrathecal Tracer Dispersion in Cynomolgus Monkey Validates Wide Biodistribution Along Neuraxis. IEEE Trans Biomed Eng. 2019; 67(4):1122-1132. DOI: 10.1109/TBME.2019.2930451. View

Loth F, Yardimci M, Alperin N . Hydrodynamic modeling of cerebrospinal fluid motion within the spinal cavity. J Biomech Eng. 2001; 123(1):71-9. DOI: 10.1115/1.1336144. View

Chen M, Lonser R, Morrison P, Governale L, Oldfield E . Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg. 1999; 90(2):315-20. DOI: 10.3171/jns.1999.90.2.0315. View

Calias P, Banks W, Begley D, Scarpa M, Dickson P . Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. Pharmacol Ther. 2014; 144(2):114-22. DOI: 10.1016/j.pharmthera.2014.05.009. View

10.

Hsu Y, Linninger A . Quantitative integration of biological, pharmacokinetic, and medical imaging data for organ-wide dose-response predictions. IEEE Trans Biomed Eng. 2013; 60(3):625-32. DOI: 10.1109/TBME.2013.2244893. View

11.

Hassenbusch S, Portenoy R . Current practices in intraspinal therapy--a survey of clinical trends and decision making. J Pain Symptom Manage. 2000; 20(2):S4-11. DOI: 10.1016/s0885-3924(00)00203-7. View

12.

Bernards C, Shen D, Sterling E, Adkins J, Risler L, Phillips B . Epidural, cerebrospinal fluid, and plasma pharmacokinetics of epidural opioids (part 1): differences among opioids. Anesthesiology. 2003; 99(2):455-65. DOI: 10.1097/00000542-200308000-00029. View

13.

Begley D . Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004; 104(1):29-45. DOI: 10.1016/j.pharmthera.2004.08.001. View

14.

Monine M, Norris D, Wang Y, Nestorov I . A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. J Pharmacokinet Pharmacodyn. 2021; 48(5):639-654. DOI: 10.1007/s10928-021-09761-0. View

15.

Tangen K, Narasimhan N, Sierzega K, Preden T, Alaraj A, Linninger A . Clearance of Subarachnoid Hemorrhage from the Cerebrospinal Fluid in Computational and In Vitro Models. Ann Biomed Eng. 2016; 44(12):3478-3494. DOI: 10.1007/s10439-016-1681-8. View

16.

Scoles D, Minikel E, Pulst S . Antisense oligonucleotides: A primer. Neurol Genet. 2019; 5(2):e323. PMC: 6501637. DOI: 10.1212/NXG.0000000000000323. View

17.

Tangen K, Hsu Y, Zhu D, Linninger A . CNS wide simulation of flow resistance and drug transport due to spinal microanatomy. J Biomech. 2015; 48(10):2144-54. DOI: 10.1016/j.jbiomech.2015.02.018. View

18.

Biliouris K, Gaitonde P, Yin W, Norris D, Wang Y, Henry S . A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. CPT Pharmacometrics Syst Pharmacol. 2018; 7(9):581-592. PMC: 6157691. DOI: 10.1002/psp4.12323. View

19.

Linge S, Haughton V, Lovgren A, Mardal K, Langtangen H . CSF flow dynamics at the craniovertebral junction studied with an idealized model of the subarachnoid space and computational flow analysis. AJNR Am J Neuroradiol. 2009; 31(1):185-92. PMC: 7964070. DOI: 10.3174/ajnr.A1766. View

20.

Coenen W, Gutierrez-Montes C, Sincomb S, Criado-Hidalgo E, Wei K, King K . Subject-Specific Studies of CSF Bulk Flow Patterns in the Spinal Canal: Implications for the Dispersion of Solute Particles in Intrathecal Drug Delivery. AJNR Am J Neuroradiol. 2019; 40(7):1242-1249. PMC: 7048533. DOI: 10.3174/ajnr.A6097. View